Last updated on April 2019

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Clinical Study Identifier: NCT03178552

Find a site near you

Start Over

Illinois Cancer Care

Peoria, IL United States
  Connect »

Cancer Inst. of New Jersey

New Brunswick, NJ United States
  Connect »

Ohio State University

Columbus, OH United States
  Connect »

Oregon HSU

Portland, OR United States
  Connect »

Oncology Consultants PA

Houston, TX United States
  Connect »

UZ Brussel

Brussel, Belgium
  Connect »

IUCPQ (H pital Laval)

Quebec City, QC Canada
  Connect »

National Cancer Center

Gyeonggi-do, Korea, Republic of
  Connect »

Florida Cancer Specialist, North Region

Saint Petersburg, FL United States
  Connect »

CHU Poitiers

Poitiers, France
  Connect »

UMCG

NL -groningen, Netherlands
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Hospital Italiano

Buenos Aires, Argentina
  Connect »

Hospital Britanico de Buenos Aires

Ciudad Autonoma Buenos Aires, Argentina
  Connect »

Clinica CIMCA

San Jose, Costa Rica
  Connect »

Oncologico Potosino

San Luis Potosí, Mexico
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.